|Day Low/High||92.13 / 93.34|
|52 Wk Low/High||72.30 / 96.31|
Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
If we can advance without China then who the heck knows where we can go with it.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
CBD could make coffee an around the clock craze.
One of pharma's biggest CEO's talks M&A action on the exchange.
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
The stock's performance has been impressive in the past three months.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Pot stock partnerships are a gateway to gains for cannabis investors.
Tilray will have a lot to tackle this evening.
It's time for the central bank to show the same level of concern for their misplaced aggression.
Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.
Let's check out the latest charts and indicators for some technical guidance.
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Here are two I think will bounce back before the end of the year.
These names are showing bullish or bearish reversal patterns over the past week.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
Happy Friday! These are the stories you must know ahead of the opening bell.
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.